Epidermal growth factor receptor

| Main Article
| Discussion
| Related Articles  [?]
| Bibliography  [?]
| External Links  [?]
| Citable Version  [?]

|
|
|
|
|
|
|
|

This editable Main Article is under development and subject to a disclaimer.

[edit intro]

In biochemistry, epidermal growth factor receptor 2 (EGFR, erbB-1, HER1, HER-1) is a cell surface receptor that is a "involved in regulation of cell growth and differentiation. It is specific for epidermal growth factor and EGF related peptides including transforming growth factor alpha, amphiregulin, and heparin-binding EGF-like growth factor. The binding of ligand to the receptor causes activation of its intrinsic tyrosine kinase activity and rapid internalization of the receptor-ligand complex into the cell."[1]

Cetuximab (IMC-C225) is a recombinant, human/mouse chimeric monoclonal antibody that binds to EGFR and may treat head and neck cancers, colorectal cancer, and non-small cell lung cancer in patients who do not have mutations in the KRAS gene.[2] Panitumumab is also a monoclonal antibody that binds to EGFR and may treat colorectal cancer.

## References[edit]

1. ↑ Anonymous (2025), Epidermal growth factor receptor (English). Medical Subject Headings. U.S. National Library of Medicine.
2. ↑ Van Cutsem E, Köhne CH, Hitre E, Zaluski J, Chang Chien CR, Makhson A et al. (2009). "Cetuximab and chemotherapy as initial treatment for metastatic colorectal cancer.". N Engl J Med 360 (14): 1408-17. DOI:10.1056/NEJMoa0805019. PMID 19339720. Research Blogging.